|
1
|
Siegel R, Naishadham MA and Jemal A:
Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Knowles MA: Molecular subtypes of bladder
cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis.
27:361–373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein JP, Lieskovsky G, Cote R, Groshen S,
Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M,
et al: Radical cystectomy in the treatment of invasive bladder
cancer: Long-term results in 1,054 patients. J Clin Oncol.
19:666–675. 2001.PubMed/NCBI
|
|
4
|
Hautmann RE, Gschwend JE, de Petriconi RC,
Kron M and Volkmer BG: Cystectomy for transitional cell carcinoma
of the bladder: Results of a surgery only series in the neobaldder
era. J Urol. 176:486–492. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shariat SF, Karakiewicz PI, Palapattu GS,
Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ,
Sagalowsky AI, et al: Outcomes of radical cystectomy for
transitional cell carcinoma of the bladder: A comtemporary series
from the Bladder Cancer Research Consortium. J Urol. 176:2414–2422.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dinney CP, McConkey DJ, Millikan RE, Wu X,
Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi
AL, et al: Focus on bladder cancer. Cancer Cell. 6:111–116. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi Y, Saika T, Manabe D, Nasu Y and
Kumon H: Prognostic factors influencing survival after
nephroureterectomy for transitional cell carcinoma of the upper
urinary tract. Acta Med Okayama. 65:143–149. 2011.PubMed/NCBI
|
|
8
|
Hall MC, Womack S, Sagalowsky AI, Carmody
T, Erickstad MD and Roehrborn CG: Prognostic factors, recurrence,
and survival in transitional cell cartinoma of the upper tract: A
30-year experience in 252 patients. Urology. 52:594–601. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Casey RG, Catto JWF, Cheng L, Cookson MS,
Herr H, Shariat S, Witjes JA and Black PC: Diagnosis and management
of urothelial carcinoma in situ of the lower urinary tract: A
systematic review. Eur Urol. 67:876–888. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grossman HB, Natale RB, Tangen CM,
Speights VO, Vogelzang NJ, Trump DL, White RW deVere, Sarosdy MF,
Wood DP Jr, Raghavan D and Crawford ED: Neoadjuvant chemotherapy
plus cystectomy compared with cystectomy alone for locally advanced
bladder cancer. N Engl J Med. 349:859–866. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI
|
|
12
|
Shariat SF, Karakiewicz PI, Ashfaq R,
Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI and Lotan Y:
Multiple biomarkers improve prediction of bladder cancer recurrence
and mortality in patients undergoing cystectomy. Cancer.
112:315–325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shariat SF, Zlotta AR, Ashfaq R,
Sagalowsky AI and Lotan Y: Cooperative effect of cell-cycle
regulators expression on bladder cancer development and biological
aggressiveness. Mod Pathol. 20:445–459. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shariat SF, Chade DC, Karakiewicz PI,
Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U,
Jeldres C, et al: Combination of multiple markers can improve
prognostication in patients with locally advanced and lymph node
positive bladder cancer. J Urol. 183:68–75. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo RF and Ward PA: Role of C5a in
inflammatory responses. Annu Rev Immunol. 23:821–852. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Markiewski MM and Lambris JD: The role of
complement in inflammatory diseases from behind the scenes into the
spotlight. Am J Pathol. 171:715–727. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niculescu F, Rus HG, Retegan M and Vlaicu
R: Persistent complement activation on tumor cells in breast
cancer. Am J Pathol. 140:1039–1043. 1992.PubMed/NCBI
|
|
18
|
Bjørge L, Hakulinen J, Vintermyr OK, Jarva
H, Jensen TS, Iversen OE and Meri S: Ascitic complement system in
ovarian cancer. Br J Cancer. 92:895–905. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Markiewski MM, DeAngelis RA, Benencia F,
Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G and
Lambris JD: Modulation of the antitumor immune response by
complement. Nat Immunol. 9:1225–1235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Corrales L, Ajona D, Rafail S, Lasarte JJ,
Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM and
Pio R: Anaphylatoxin C5a creates a favorable microenvironment for
lung cancer progression. J Immunol. 189:4674–4683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gerard NP and Gerard C: The chemotactic
receptor for human C5a anaphylatoxin. Nature. 349:614–617. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nitta H, Wada Y, Kawano Y, Murakami Y,
Irie A, Taniguchi K, Kikuchi K, Yamada G, Suzuki K, Honda J, et al:
Enhancement of human cancer cell motility and invasiveness by
anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
Clin Cancer Res. 19:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nitta H, Murakami Y, Wada Y, Eto M, Baba H
and Imamura T: Cancer cells release anaphylatoxin C5a from C5 by
serine protease to enhance invasiveness. Oncol Rep. 32:1715–1719.
2014.PubMed/NCBI
|
|
24
|
Cho MS, Vasquez HG, Rupaimoole R, Pradeep
S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J,
Huang J, et al: Autocrine effects of tumor-derived complement. Cell
Rep. 6:1085–1095. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: World Health Organization Classification of
TumoursPathology and Genetics of Tumours of the Urinary System and
Male Genital Organs. IARC Press; Lyon: 2004
|
|
26
|
Mostofi FK, Sobin LH and Torloni H:
Histological typing of urinary bladder tumoursInternational
Classification of Tumours. 10. World Health Organization; Geneva:
1973
|
|
27
|
Shariat SF, Sfakianos JP, Droller MJ,
Karakiewicz PI, Meryn S and Bochner BH: The effect of age and
gender on bladder cancer: A critical review of the literature. BJU
Int. 105:300–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lughezzani G, Burger M, Margulis V, Matin
SF, Novara G, Roupret M, Shariat SF, Wood CG and Zigeuner R:
Prognostic factors in upper urinary tract urothelial carcinomas: A
comprehensive review of the current literature. Eur Urol.
62:100–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Simone G, Papalia R, Loreto A, Leonardo C,
Sentinelli S and Gallucci M: Independent prognostic value of tumour
diameter and tumournecrosis in upper urinary tract urothelial
carcinoma. BJU Int. 103:1052–1057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kikuchi E, Margulis V, Karakiewicz PI,
Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer
A, et al: Lymphovascular invasion predicts clinical outcomes in
patients with node-negative upper tract urothelial carcinoma. J
Clin Oncol. 27:612–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karam JA, Lotan Y, Karakiewicz PI, Ashfaq
R, Sagalowsky AI, Roehrborn CG and Shariat SF: Use of combined
apoptosis biomarkers for predicition of bladder cancer recurrence
and mortality after radical cystectomy. Lancet Oncol. 8:128–136.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lalli PN, Strainic MG, Yang M, Lin F,
Medof ME and Heeger PS: Locally produced C5a binds to T
cell-expressed C5aR to enhance effector T-cell expansion by
limiting antigen-induced apoptosis. Blood. 112:1759–1766. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bénard M, Gonzalez BJ, Schouft MT,
Falluel-Morel A, Vaudry D, Chan P, Vaudry H and Fontaine M:
Characterization of C3a and C5a receptors in rat cellebellar
granule neurons during maturation. Neuroprotective effect of C5a
against apoptotic cell death. J Biol Chem. 279:43487–43496. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shariat SF, Ashfaq R, Karakiewicz PI,
Saeedi O, Sagalowsky AI and Lotan Y: Survivin expression is
associated with bladder cancer presence, stage, progression and
mortality. Cancer. 109:1106–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
